Jardiance Drives Boehringer Ingelheim Through First Half, Market Volatility Expected To Continue

Total Pharma Sales Up By 4.4%

Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.  

Boehringer
• Source: Shutterstock

The diabetes therapy, Jardiance (empagliflozin) is continuing to be a key driver of growth at the family-owned, Germany-headquartered Boehringer Ingelheim GmbH, with currency-adjusted net sales of €1.2bn in the first half of 2020, up by 22.7% compared with sales of around €1bn in the first half of 2019.

Boehringer Ingelheim is also continuing to support the use of empagliflozin in additional indications including its use in patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By 

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By 

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

Shigella Vaccine Pipeline And Why It Matters

 
• By 

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.